IGS1.F · India Globalization Capital, Inc

-

Please sign in to comment on IGS1.F

1 Comment

Admin

4 years ago

India Globalization Capital, Inc is currently in a long term downtrend where the price is trading 2.7% below its 200 day moving average.

From a valuation standpoint, the stock is 432.4% more expensive than other stocks from the Industrials sector with a price to sales ratio of 83.5.

India Globalization Capital, Inc's total revenue sank by 81.2% to $108K since the same quarter in the previous year.

Its net income has dropped by 44.9% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 48.9% to $-2M since the same quarter in the previous year.

Based on the above factors, India Globalization Capital, Inc gets an overall score of 1/5.

Exchange	F
CurrencyCode	EUR
ISIN	US45408X3089
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Target Price	None
Market Cap	20M
Beta	1.45
Dividend Yield	None

ABOUT

India Globalization Capital, Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGS1.F · India Globalization Capital, Inc

-

India Globalization Capital, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest India Globalization Capital, Inc using a moving average strategy